PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma

British Journal of Cancer

Volumn 112, Issue 12, 2015, Pages 1938-1943

  Beg, S ^a   Siraj, A K ^a   Jehan, Z ^a   Prabakaran, S ^a   Al Sobhi, S S ^a   Al Dawish, M ^b   Al Dayel, F ^a   Al Kuraya, K S ^a,c  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b The General Directorate of Armed Forces Health Services   (Saudi Arabia)

^c ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Follicular variant; Papillary thyroid cancer; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIDDLE EAST; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; TISSUE MICROARRAY; ADOLESCENT; AGED; CARCINOMA; CHILD; COHORT ANALYSIS; DEFICIENCY; ENZYMOLOGY; GENETICS; MUTATION; THYROID TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHILD; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MIDDLE EAST; MUTATION; PTEN PHOSPHOHYDROLASE; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84930867253     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.169     Document Type: Article

References (42)

1. Alvarez-Nunez F, Bussaglia E, Mauricio D, Ybarra J, Vilar M, Lerma E, de Leiva A, Matias-Guiu X (2006) PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16(1): 17-23.
2. Antonelli A, Fallahi P, Ferrari SM, Ruffilli I, Santini F, Minuto M, Galleri D, Miccoli P (2011) New targeted therapies for thyroid cancer. Curr Genomics 12(8): 626-631.
3. Bazarbashi S (2010) Cancer Incidence report Saudi Arabia, 21.
4. Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, Fusco A, Viglietto G (2000) PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 19(28): 3146-3155.
5. Campos M, Kool MM, Daminet S, Ducatelle R, Rutteman G, Kooistra HS, Galac S, Mol JA (2014) Upregulation of the PI3K/Akt pathway in the tumorigenesis of canine thyroid carcinoma. J Vet Intern Med 28(6): 1814-1823.
6. Carracedo A, Pandolfi PP (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27(41): 5527-5541.
7. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17(3): 590-603.
8. Cordes I, Kluth M, Zygis D, Rink M, Chun F, Eichelberg C, Dahlem R, Fisch M, Hoppner W, Wagner W, Doh O, Terracciano L, Simon R, Wilczak W, Sauter G, Minner S (2013) PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer. Histopathology 63(5): 670-677.
9. D M, T MK, Khan DM, Raman RT (2014) Follicular variant of papillary thyroid carcinoma: cytological indicators of diagnostic value. J Clin Diagn Res 8(3): 46-48.
10. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C (1997) Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57(21): 4710-4713.
11. Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA (2014) Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta 1855(1): 104-121.
12. Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295(18): 2164-2167.
13. Duman BB, Kara OI, Uguz A, Ates BT (2014) Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma. Contemp Oncol (Pozn) 18(4): 234-240.
14. Georgescu MM (2010) PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 1(12): 1170-1177.
15. Goschzik T, Gessi M, Denkhaus D, Pietsch T (2014) PTEN mutations and activation of the PI3K/Akt/mTOR signaling pathway in papillary tumors of the pineal region. J Neuropathol Exp Neurol 73(8): 747-751.
16. Hagag P, Hod N, Kummer E, Cohenpour M, Horne T, Weiss M (2006) Follicular variant of papillary thyroid carcinoma: clinical-pathological characterization and long-term follow-up. Cancer J 12(4): 275-282.
17. Halachmi N, Halachmi S, Evron E, Cairns P, Okami K, Saji M, Westra WH, Zeiger MA, Jen J, Sidransky D (1998) Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 23(3): 239-243.
18. Hou P, Ji M, Xing M (2008) Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113(9): 2440-2447.
19. Hunt JL, Fowler M, Lomago D, Niehouse L, Sasatomi E, Swalsky P, Finkelstein S (2004) Tumor suppressor gene allelic loss profiles of the variants of papillary thyroid carcinoma. Diagn Mol Pathol 13(1): 41-46.
20. Hussain F, Iqbal S, Mehmood A, Bazarbashi S, ElHassan T, Chaudhri N (2013) Incidence of thyroid cancer in the Kingdom of Saudi Arabia, 2000-2010. Hematol Oncol Stem Cell Ther 6(2): 58-64.
21. Ito Y, Nikiforov YE, Schlumberger M, Vigneri R (2013) Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol 9(3): 178-184.
22. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7): 844-847.
23. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK, Xing M (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93(8): 3106-3116.
24. Lotan TL, Carvalho FL, Peskoe SB, Hicks JL, Good J, Fedor HL, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM (2015) PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol 28(1): 128-137.
25. Manfredi GI, Dicitore A, Gaudenzi G, Caraglia M, Persani L, Vitale G (2014) PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. Endocrine 48(2): 363-370.
26. Min HS, Lee C, Jung KC (2013) Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J Korean Med Sci 28(4): 534-541.
27. Nilsson IL, Arnberg F, Zedenius J, Sundin A (2011) Thyroid incidentaloma detected by fluorodeoxyglucose positron emission tomography/computed tomography: practical management algorithm. World J Surg 35(12): 2691-2697.
28. Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Ghossein R, Michael Tuttle R, Shaha AR, Shah JP (2012) Changing trends in well differentiated thyroid carcinoma over eight decades. Int J Surg 10(10): 618-623.
29. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R (2013) Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013: 965212.
30. Piras G, Monne M, Palmas AD, Calvisi A, Asproni R, Vacca F, Pilo L, Gabbas A, Latte G (2014) Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma. Clin Epigenetics 6(1): 16.
31. Porta C, Paglino C, Mosca A (2014) Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol 4: 64.
32. Salajegheh A, Petcu EB, Smith RA, Lam AK (2008) Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists. Postgrad Med J 84(988): 78-82.
33. Sozopoulos E, Litsiou H, Voutsinas G, Mitsiades N, Anagnostakis N, Tseva T, Patsouris E, Tseleni-Balafouta S (2010) Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. Endocr Pathol 21(2): 90-100.
34. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15(4): 356-362.
35. Sun Z, Huang C, He J, Lamb KL, Kang X, Gu T, Shen WH, Yin Y (2014) PTEN C-terminal deletion causes genomic instability and tumor development. Cell Rep 6(5): 844-854.
36. Torres J, Pulido R (2001) The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 276(2): 993-998.
37. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20(14): 5010-5018.
38. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 95(9): 5246-5250.
39. Yang Z, Yuan XG, Chen J, Luo SW, Luo ZJ, Lu NH (2013) Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: a novel mechanism of PTEN inactivation. Clin Res Hepatol Gastroenterol 37(1): 72-79.
40. Yu XM, Schneider DF, Leverson G, Chen H, Sippel RS (2013) Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid 23(10): 1263-1268.
41. Yun M, Noh TW, Cho A, Choi YJ, Hong SW, Park CS, Lee JD, Kim CK (2010) Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. J Clin Endocrinol Metab 95(7): 3182-3188.
42. Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A (2003) Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 97(5): 1181-1185.